Opening the Door to Medtronic
Viant’s neuromodulation pedigree and Koneru’s Medtronic ties create a natural bridge.
VLMS’s equity model allows Medtronic to participate without bureaucracy—just by acquiring shares.
BIEL’s PEMF wearables could evolve into non-invasive VNS devices, especially with Viant’s smart device engineering and VLMS’s AI backend.
Strategic Synergy: Viant + VLMS + BIEL
Viant Medical brings neuromodulation engineering expertise, including connections to Medtronic’s device ecosystem via board member Dr. Sree Koneru.
VLMS Healthcare offers AI-driven distribution and reimbursement infrastructure, which is essential for scaling vagus nerve stimulation (VNS) therapies.
BIEL’s ActiPatch and RecoveryRx platforms use PEMF (pulsed electromagnetic field) therapy, which shares mechanistic overlap with non-invasive neuromodulation.
Together, they form a connected pain platform that’s FDA-cleared, scalable, and digitally enabled—a perfect launchpad for VNS expansion.
Why Vagus Nerve Stimulation Matters
VNS is FDA-approved for epilepsy, depression, stroke rehab, and under study for inflammation, anxiety, and chronic pain4.
New techniques like intermittent interferential current stimulation (i²CS) allow precise fiber targeting, reducing side effects and improving efficacy.
Medtronic is actively developing next-gen VNS implants, and partnerships with scalable platforms like BIEL could accelerate adoption.
What’s Next?
If BIEL integrates adaptive PEMF modulation, HRV tracking, and smartwatch connectivity, it could rival Vielight and other VNS innovators—but with FDA clearance and retail access already in hand.
Viant’s neuromodulation pedigree and Koneru’s Medtronic ties create a natural bridge.
VLMS’s equity model allows Medtronic to participate without bureaucracy—just by acquiring shares.
BIEL’s PEMF wearables could evolve into non-invasive VNS devices, especially with Viant’s smart device engineering and VLMS’s AI backend.
Strategic Synergy: Viant + VLMS + BIEL
Viant Medical brings neuromodulation engineering expertise, including connections to Medtronic’s device ecosystem via board member Dr. Sree Koneru.
VLMS Healthcare offers AI-driven distribution and reimbursement infrastructure, which is essential for scaling vagus nerve stimulation (VNS) therapies.
BIEL’s ActiPatch and RecoveryRx platforms use PEMF (pulsed electromagnetic field) therapy, which shares mechanistic overlap with non-invasive neuromodulation.
Together, they form a connected pain platform that’s FDA-cleared, scalable, and digitally enabled—a perfect launchpad for VNS expansion.
Why Vagus Nerve Stimulation Matters
VNS is FDA-approved for epilepsy, depression, stroke rehab, and under study for inflammation, anxiety, and chronic pain4.
New techniques like intermittent interferential current stimulation (i²CS) allow precise fiber targeting, reducing side effects and improving efficacy.
Medtronic is actively developing next-gen VNS implants, and partnerships with scalable platforms like BIEL could accelerate adoption.
What’s Next?
If BIEL integrates adaptive PEMF modulation, HRV tracking, and smartwatch connectivity, it could rival Vielight and other VNS innovators—but with FDA clearance and retail access already in hand.
1
